Welcome to our dedicated page for 4D Molecular Therapeutics news (Ticker: FDMT), a resource for investors and traders seeking the latest updates and insights on 4D Molecular Therapeutics stock.
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) is a late-stage biotechnology company developing durable, disease-targeted genetic medicines. News about 4D Molecular Therapeutics often focuses on progress in its lead programs, 4D-150 for retinal vascular diseases and 4D-710 for cystic fibrosis lung disease, as well as corporate, financial and partnership developments.
For ophthalmology, company updates highlight clinical data and milestones for 4D-150 in wet age-related macular degeneration and diabetic macular edema. These include interim results from the PRISM Phase 1/2 trial, enrollment and design details for the 4FRONT Phase 3 program, and plans for global Phase 3 trials in DME. News items also cover collaborations, such as the license and development agreement with Otsuka Pharmaceutical for 4D-150 in Asia-Pacific markets.
In pulmonology, 4DMT news includes interim clinical data from the AEROW Phase 1/2 trial of 4D-710 in cystic fibrosis lung disease, describing CFTR transgene expression, lung function measures and dose selection for Phase 2. Additional coverage addresses external support, including an equity investment from the Cystic Fibrosis Foundation to help advance 4D-710.
Investors can also find announcements on equity offerings, cash runway guidance, leadership changes, board appointments, employment inducement grants and participation in healthcare and investor conferences. This news page aggregates these updates so readers can follow clinical progress, strategic partnerships, capital markets activity and governance developments related to FDMT over time.
4D Molecular Therapeutics announced the dosing of the first patient in its Phase 1/2 clinical trial of 4D-310, aimed at treating Fabry disease, a condition with significant unmet medical needs. The trial will evaluate safety, tolerability, and activity of the therapy, with enrollment set for up to 18 patients. 4D-310 employs a novel dual mechanism targeting AGA enzyme activity in blood and affected tissues, addressing limitations of current enzyme replacement therapies. This advancement highlights the company's commitment to innovative gene therapies.
4D Molecular Therapeutics has successfully closed its initial public offering, selling 9,660,000 shares at $23.00 each, totaling approximately $222 million in gross proceeds. The offering included 1,260,000 shares from the underwriters' option. Shares began trading on the Nasdaq under the ticker symbol FDMT. The company specializes in gene therapy using directed evolution and is currently engaged in three clinical trials targeting ophthalmology, cardiology, and pulmonology, aiming to enhance delivery efficacy while minimizing immunogenicity.